Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2012
03/15/2012US20120064126 Dry powder formulations and methods for treating pulmonary diseases
03/15/2012US20120064123 Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
03/15/2012US20120064122 Treatment of autoimmune inflammation using mir-155
03/15/2012US20120064121 Pyridine compounds for inflammation and immune-related uses
03/15/2012US20120064116 Influenza nucleic acid molecules and vaccines made therefrom
03/15/2012US20120064107 Compositions and methods for treatment of autoimmune and other disease
03/15/2012US20120064099 Compounds that inhibit nfkb and bace1 activity
03/15/2012US20120064094 Serotonin 5-HT3 Receptor Antagonists for Use in the Treatment of Lesional Vestibular Disorders
03/15/2012US20120064092 Novel Target for Regulating Multiple Sclerosis
03/15/2012US20120064090 Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug
03/15/2012US20120064089 Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
03/15/2012US20120064088 Methods of treating aneurysm
03/15/2012US20120064075 Chimeric factor vii molecules with enhanced half life and methods of use
03/15/2012US20120064072 Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
03/15/2012US20120064071 Treatment of cancer
03/15/2012US20120064062 Inhibitors of bacterial plasminogen activators
03/15/2012US20120064060 Compound having s1p receptor binding potency and use thereof
03/15/2012US20120064056 Dichloracetate in combination with clinically high levels of cardioprotective or hemodynamic drugs
03/15/2012US20120064054 Pharmaceutical compositions active in preventing, stabilizing and treating alzheimer's disease
03/15/2012US20120064048 Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
03/15/2012US20120064044 Methods of treating edema related to ischemia-reperfusion
03/15/2012US20120064036 Methods of Administration of Thrombopoietin Agonist Compounds
03/15/2012US20120064034 Peptidomimetic protease inhibitors
03/15/2012US20120064032 Novel hydroxamates as therapeutic agents
03/15/2012US20120064027 Absorbable adhesive paste
03/15/2012US20120064025 Quinazolinone Modulators Of Nuclear Receptors
03/15/2012US20120064021 Dendrobium chysotoxum extract and its cosmetic use as an anti-aging agent
03/15/2012US20120064013 Foamable topical composition
03/15/2012US20120064008 Compositions for the treatment of metastatic cancer and methods of use thereof
03/15/2012US20120064007 Methods of using sustained release aminopyridine compositions
03/15/2012US20120064004 Isotopologues of thalidomide
03/15/2012US20120063999 Psca: prostate stem cell antigen and uses thereof
03/15/2012US20120063996 Novel nimesulide compositions
03/15/2012US20120063994 Rtef-1 variants and uses thereof
03/15/2012US20120061267 MediTowel Anti-Fungal Wipe
03/15/2012US20120060258 Composition for use in decreasing the transmission of human pathogens
03/15/2012DE102010045366A1 Treating and preventing migraine and migraine/cluster-like headaches, comprises administering creatine derivatives
03/15/2012DE102010045185A1 Stoffgemisch, Verwendung und Infusionslösung Mixture, use and infusion
03/15/2012CA2842454A1 Nasal spray
03/15/2012CA2812034A1 Methods for concomitant treatment of theophylline and febuxostat
03/15/2012CA2811454A1 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a b-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof
03/15/2012CA2811145A1 Sesterterpene compound and use thereof
03/15/2012CA2811025A1 Hetero ring-fused imidazole derivative having ampk activating effect
03/15/2012CA2810950A1 Sdf-1 binding nucleic acids and the use thereof in cancer treatment
03/15/2012CA2810858A1 Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors
03/15/2012CA2810844A1 Treatment of diseases
03/15/2012CA2810834A1 Treatment of diseases
03/15/2012CA2810755A1 Substituted imidazopyridazines
03/15/2012CA2810742A1 Hybrid cooperative complexes of hyaluronic acid
03/15/2012CA2810698A1 Composition for preventing inflammations
03/15/2012CA2810696A1 Pyrazoloquinoline compound
03/15/2012CA2810659A1 Quinoxaline compound
03/15/2012CA2810590A1 Mercapto-modified biocompatible macromolecule derivatives with low degree of mercapto-modification and the cross-linked materials and uses thereof
03/15/2012CA2810537A1 Compositions for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
03/15/2012CA2810528A1 Compounds as c-met kinase inhibitors
03/15/2012CA2810499A1 P53-mdm2 antagonists
03/15/2012CA2810489A1 Prostaglandin d synthase inhibitory piperidine compounds
03/15/2012CA2810481A1 Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
03/15/2012CA2810468A1 Conjugates of polyunsaturated fatty acids and amine-containing compounds and uses thereof
03/15/2012CA2810283A1 Process for producing crystalline 5-aminosalicylic acid
03/15/2012CA2810021A1 Boron-containing small molecules
03/15/2012CA2809927A1 A transdermal drug administration device
03/15/2012CA2809778A1 Therapeutic agent for pain
03/15/2012CA2809736A1 N-hydroxy-benzamides for the treatment of cancer
03/15/2012CA2809203A1 Novel use
03/15/2012CA2808959A1 Quinoline and quinoxaline derivatives as kinase inhibitors
03/15/2012CA2808724A1 1,5-diaryl-2-alkylpyrrole-3-substituted nitro esters, selective cox-2 inhibitors and nitric oxide donors
03/15/2012CA2808665A1 Heteroarylmethyl amides
03/14/2012EP2428577A1 Preparation of tyrosinase-inhibiting hydroxybenzyl and hydroxypyranonemethyl esters
03/14/2012EP2428516A1 Novel phosphorus-containing thyromimetics
03/14/2012EP2428515A1 Spiro-oxindole compounds and their uses as therapeutic agents
03/14/2012EP2428514A1 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
03/14/2012EP2428513A1 5-substituted quinazolinone derivatives as anti-cancer agents
03/14/2012EP2428510A2 Preparation of taxanes from 9-dihydro-13-acetylbaccatin III
03/14/2012EP2428509A1 Human adam-10 inhibitors
03/14/2012EP2428508A1 Diamino heterocyclic carboxamide compound
03/14/2012EP2428507A2 Cannabinoid receptor ligands
03/14/2012EP2428506A1 Heterocyclic substituted acardite derivates and use thereof
03/14/2012EP2428234A1 Composition for use in treating retinal cell death and in reducing intraocular pressure
03/14/2012EP2428217A1 Composition based on docosahexaenoic acid (dha) for use in the treatment of cystic fibrosis and non-alcoholic hepatic steatosis
03/14/2012EP2428213A1 Stabilized chlorite solutions in combination with fluoropyrimidines for use in cancer treatment
03/14/2012EP2428212A1 Material mixture, use and infusion solution comprising ribose, alanin, nicotinic acid and ascorbic acid
03/14/2012EP2428211A2 Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases
03/14/2012EP2428210A1 Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
03/14/2012EP2428209A1 Drug suitability assessment method for prevention or treatment of anxiety disorders using cholinergic type ii theta rhythm
03/14/2012EP2428207A1 Alpha-2B adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
03/14/2012EP2428204A2 pH sensitive matrix formulation
03/14/2012EP2428203A1 A nano-emulsion injection of vinca alkaloids and the preparation method thereof
03/14/2012EP2428202A2 Orally disintegrating compositions
03/14/2012EP2428201A1 Oral administration of nucleoside monophosphates
03/14/2012EP2428117A1 Anti-inflammatory activity of phenethylisothiocyanate (PEITC) and the Barbarea verna seed preparation containing this compound
03/14/2012EP2427565A2 Glucooligosaccharides comprising (alpha 1->4) and (alpha 1->6) glycosidic bonds, use thereof, and methods for producing them
03/14/2012EP2427554A2 Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
03/14/2012EP2427553A2 Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
03/14/2012EP2427552A2 Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
03/14/2012EP2427503A1 Novel acylated decasaccharides and their use as antithrombotic agents
03/14/2012EP2427500A1 Novel acylated 1,6-anhydro decasaccharide and its use as antithrombotic agent
03/14/2012EP2427499A1 Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
03/14/2012EP2427472A1 Lipophilic polynucleotide conjugates
03/14/2012EP2427467A1 Triptolide prodrugs
1 ... 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 ... 7860